This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Rocket Stocks to Buy This Week

Stocks in this article: RMDBBTCRMIRYHOO

>>4 Big Stocks to Trade (or Not)

Ingersoll was one of many industrials that decided to tighten its belt in 2008, cutting its overhead costs and ultimately ensuring that more of every dollar it brings in makes it to the bottom line of its income statement. That's helped to generate net profit margins approaching 10% in the last year. IR's brands may not be particularly complementary, but they are mainly league-leaders in their respective niches, a fact that provides for premium pricing and a stickier customer base of after market parts.

To be sure, Ingersoll still isn't in a "normal" market for its products. Despite a pickup in construction, building is still depressed from prerecession levels. When those numbers start to pick up again, particularly on the commercial side, Ingersoll-Rand should benefit disproportionately.

In the meantime, a reasonable balance sheet and a growing emerging markets business should help investors wait things out. Just keep an eye on Friday's earnings call.

ResMed

Medical device maker RedMed (RMD) rounds out our list of Rocket Stocks this week. RMD's primary business is in manufacturing airflow generators and masks for sleep apnea patients, a business that could provide a springboard for ResMed to move into other breathing disorders with underserved device markets. The firm announces its next round of earnings on Oct. 25.

ResMed has built a business on being innovative. When the firm decided to move into the sleep apnea business, it used superior technology to take market share from the medical device makers who held the top spots. As RMD continues to innovate, it should open up new markets. New pushes toward home testing of sleep apnea should help lift the fortunes of all the medical device makers in the business, but a push toward treating other related breathing disorders holds the most promise in the longer-term.

Financially, ResMed is in good shape, with around $560 million in net cash on its balance sheet once debt is accounted for. Short sellers have historically mobilized against shares of ResMed, shoving the firm's short interest ratio in the double-digits and making this stock a good candidate for a short squeeze.

4 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,380.41 +263.17 1.63%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs